Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 5/2019

01-09-2019 | Metastasis | Original Article

Breast cancer cell motility is promoted by 14-3-3γ

Authors: Emiko Hiraoka, Takahiro Mimae, Masaoki Ito, Takayuki Kadoya, Yoshihiro Miyata, Akihiko Ito, Morihito Okada

Published in: Breast Cancer | Issue 5/2019

Login to get access

Abstract

Purpose

Pseudopodia are actin-rich ventral protrusions associated with cell motility and cancer cell invasion. We previously applied our established method of using excimer laser cell etching to isolate pseudopodial proteins from MDA-MB-231 breast cancer cells. We later identified 14-3-3γ as an oncogenic molecule among 46 candidate proteins that are specific to pseudopodia. The present study aimed to determine the function of 14-3-3γ in the motility of breast cancer cells.

Methods

MDA-MB-231 cells were cultured on 3-µm porous membranes and double stained to localize 14-3-3γ and phalloidin in pseudopodia using confocal imaging. We assessed pseudopodia numbers and length, as well as migration and wound healing in MDA-MB-231 cells with knockdown and forced expression of 14-3-3γ to determine 14-3-3γ involvement in cell motility. We also immunohistochemically analyzed 14-3-3γ in human breast cancer tissues with high-grade lymphatic invasion.

Results

We specifically located 14-3-3γ in pseudopodia of MDA-MB-231 cells. Knockdown and forced expression of 14-3-3γ, respectively, decreased and increased pseudopodial formation and elongation. Migration and wound healing assays also showed that 14-3-3γ knockdown and forced expression, respectively, decreased and increased the number of underside cells and acellular areas in MDA-MB-231 breast cancer cells. More 14-3-3γ was expressed in sites of lymphatic invasion, than in the center and periphery of human breast cancer tissues.

Conclusion

The role of 14-3-3γ in breast cancer invasiveness might be to promote cell motility. Inhibition of 14-3-3γ could, therefore, become a novel target of therapy to prevent invasion and metastasis in patients with breast cancers expressing 14-3-3γ.
Appendix
Available only for authorised users
Literature
1.
Guirguis R, Margulies I, Taraboletti G, Schiffmann E, Liotta L. Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature. 1987;329:261–3.CrossRefPubMed
2.
Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84(3):359–69.CrossRefPubMed
3.
Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24(2):277–83.CrossRefPubMed
4.
Ito A, Mimae T, Yamamoto YS, Hagiyama M, Nakanishi J, Ito M, Hosokawa Y, Okada M, Murakami Y, Kondo T. Novel application for pseudopodia proteomics using excimer laser ablation and two-dimensional difference gel electrophoresis. Lab Investig. 2012;92(9):1374–85.CrossRefPubMed
5.
Mimae T, Ito A. New challenges in pseudopodial proteomics by a laser-assisted cell etching technique. Biochim Biophys Acta. 2015;1854(6):538–46.CrossRefPubMed
6.
Wang X, Liu F, Qin X, Huang T, Huang B, Zhang Y, Jiang B. Expression of Rab1A is upregulate in human lung cancer and associated with tumor size and T stage. Aging. 2016;8(11):2790–8.CrossRefPubMedPubMedCentral
7.
Wang ZK, Cheng ZW, Chen SJ, Zhu XG, Gu YP, Yang XD, Sun L, Liu WT, Zhang YJ, Yuan JF, Tian KJ, Yao YZ, He SB. Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer. Eur Rev Med Pharmacol Sci. 2018;22(14):4509–17.PubMed
8.
Xu B, Huang C, Yang X, Li X, Li L, Ding Y. Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer. Oncol Lett. 2018;15(4):5185–92.PubMedPubMedCentral
9.
Xu H, Qian M, Zhao B, Wu C, Maskey N, Song H, Li D, Song J, Hua K, Fang L. Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells. Oncol Rep. 2017;37(3):1619–26.CrossRefPubMed
10.
Ito M, Hagiyama M, Mimae T, Inoue T, Kato T, Yoneshige A, Nakanishi J, Kondo T, Okada M, Ito A. α-Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):59–69.CrossRefPubMed
11.
Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889–97.CrossRefPubMed
12.
Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000;40:617–47.CrossRefPubMed
13.
14.
Aitken A, Collinge DB, van Heusden BP, Isobe T, Roseboom PH, Rosenfeld G, Soll J. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci. 1992;17(12):498–501.CrossRefPubMed
15.
Mackintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulated diverse cellular processes. Biochem J. 2004;381(Pt 2):329–42.CrossRefPubMedPubMedCentral
16.
Wu YJ, Jan YJ, Ko BS, Liang SM, Liou JY. Involvement of 14-3-3 proteins in regulating tumor progression of hepatocellular carcinoma. Cancers (Basal). 2015;7:1022–36.CrossRef
17.
Liu TA, Jan YJ, Ko BS, Chen SC, Liang SM, Hung YL, Hsu C, Shen TL, Lee YM, Chen PF, Wang J, Shyue SK, Liou JY. Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol. 2011;179(6):2698–708.CrossRefPubMedPubMedCentral
18.
Sugiyama A, Miyagi Y, Komiya Y, Kurabe N, Kitanaka C, Kato N, Nagashima Y, Kuchino Y, Tashiro F. Forced expression of antisense 14-3-3β RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis. 2003;24:1549–59.CrossRefPubMed
19.
Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, Kim SW, Yoon HY, Yoon SK. Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diamminedichloroplatinum. Cancer Lett. 2011;303(2):99–107.CrossRefPubMed
20.
Liu TA, Jan YJ, Ko BS, Liang SM, Chen SC, Wang J, Hsu C, Wu YM, Lion JY. 14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma. PLoS ONE. 2013;8(3):e57968.CrossRefPubMedPubMedCentral
21.
Ko BS, Jan YJ, Chang TC, Liang SM, Chen SC, Liu TA, Wu YM, Wang J, Liou JY. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma. Anticancer Agents Med Chem. 2013;13:555–62.CrossRefPubMed
22.
23.
Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res. 2005;4:2062–9.CrossRefPubMed
24.
Raungrut P, Wongkotsila A, Lirdprapamomgkol K, Svasti J, Geater SL, Phukaoloun M, Suwiwat S, Thonqsuksai P. Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15(8):3513–8.CrossRefPubMed
25.
Teo Z, Sng MK, Lim MMK, Li Y, Li L, Phua T, Lee JYH, Tan ZW, Zhu P, Tan NS. Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3γ expression. Oncogene. 2017;36(46):6408–19.CrossRefPubMedPubMedCentral
26.
Song Y, Yang Z, Ke Z, Yao Y, Hu X, Sun Y, Li H, Yin J, Zeng C. Expression of 14-3-3γ in patients with breast cancer: correlation with clinicopathological features and prognosis. Cancer Epidemiol. 2012;36(6):533–6.CrossRefPubMed
27.
Ajjappala BS, Kim YS, Kim MS, Lee KY, Ki HY, Cha DH, Baek KH. 14-3-3γ is stimulated by il-3 and promotes cell proliferation. J Immunol. 2009;182(2):1050–60.CrossRefPubMed
28.
Ko BS, Lai IR, Chang TC, Liu TA, Chen SC, Wang J, Liou JY. Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum Pathol. 2011;42(1):129–35.CrossRefPubMed
29.
Wang P, Deng Y, Fu X. MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 2017;482(4):935–41.CrossRefPubMed
30.
Raungrut P, Wongkotsila A, Champoochana N, Lirdprapamomgkol K, Svasti J, Svasti J, Thonqsuksai P. Knockdown of 14-3-3γ suppresses epithelial-mesenchymal transition and reduces metastatic potential of human non-small cell lung cancer cells. Anticancer Res. 2018;38(6):3507–14.CrossRefPubMed
31.
Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.CrossRef
32.
Perdigão-Henriques R, Petrocca F, Altschuler G, Thomas MP, Le MT, Tan SM, Hide W, Lieberman J. miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene. 2016;35(2):158–72.CrossRefPubMed
Metadata
Title
Breast cancer cell motility is promoted by 14-3-3γ
Authors
Emiko Hiraoka
Takahiro Mimae
Masaoki Ito
Takayuki Kadoya
Yoshihiro Miyata
Akihiko Ito
Morihito Okada
Publication date
01-09-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00957-4

Other articles of this Issue 5/2019

Breast Cancer 5/2019 Go to the issue

Original Article

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer

Original Article

C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis

Original Article

PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation

Original Article

Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan

Correction

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Original Article

Oncologic outcomes and radiation safety of nipple-sparing mastectomy with intraoperative radiotherapy for breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits